New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid.

ABSTRACT:

Background and aims

Azathioprine (AZA) is widely used for the treatment of inflammatory bowel disease (IBD) patients. AZA is catabolized by thiopurine S-methyltransferase (TPMT), which exhibits genetic polymorphisms. It has also been reported that 5-aminosalicylic acid (5-ASA) inhibits TPMT activity, and that increased 6-thioguanine nucleotide (6-TGN, a metabolite of AZA) blood concentrations result in an increased number of ADRs. In this study, single nucleotide polymorphisms (SNPs) related to differential gene expression affecting AZA drug metabolism in combination therapy with 5-ASA were examined.

Methods

To identify genetic biomarkers for the prediction of 6-TGN blood concentration, ExpressGenotyping analysis was used. ExpressGenotyping analysis is able to detect critica

SUBMITTER: Uchiyama K 

PROVIDER: S-EPMC3999094 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature